Navigation Links
Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
Date:8/7/2008

four New Drug Applications pending at the FDA.

Selling, General and Administrative

The Company's SG&A expenses totaled $221 million during the second quarter of 2008, compared to $188 million in the prior year period. SG&A for the first six months of 2008 totaled $415 million, compared to $367 million for the prior year period. The increases in SG&A were primarily related to increases in sales and marketing costs related to the promotion of the Company's proprietary products in the U.S. and the impact of foreign currency exchange.

Interest Expense/Income and Other (Expense) Income

During the second quarter of 2008, the Company recorded $27 million of interest expense, almost all of which is related to interest on the debt incurred in connection with the Company's acquisition of PLIVA in October 2006. In addition, during the second quarter of 2008, the Company recorded interest income of $7 million and other income of less than $1 million.

Tax Rate

The Company's tax rate for the second quarter of 2008 was 46.1%, compared to 35.4% for the prior year period. The rate in 2008 was negatively impacted by a change of the mix of income in certain U.S. and foreign taxing jurisdictions and the expiration of the U.S. research and development tax credit at December 31, 2007, offset partially by a reduction of the tax rate in Germany. In 2007, the rate was positively impacted by the reinstatement of the Croatian research and development incentive and benefits resulting from positive audit settlements in various tax jurisdictions.

The effective tax rate for adjusted earnings for the second quarter of 2008 was 38.0%.

Balance Sheet

The Company's cash, cash equivalents and short-term marketable securities totaled approximately $547 million at June 30, 2008. In addition, the Company had $21 million of long-term marketable securities at June 30, 2008.

EBITDA

Earnings before interest, taxes, depreciation and a
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
2. Caliper Life Sciences Reports Second Quarter 2008 Results
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. EntreMed Reports Second Quarter 2008 Financial Results
5. Transgenomic Reports Second Quarter 2008 Results
6. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
7. Bionovo Reports Second Quarter 2008 Financial Results
8. AtriCure Reports Record Second Quarter 2008 Financial Results
9. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
10. eResearchTechnology Reports Second Quarter 2008 Results
11. SuperGen Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
(Date:7/10/2014)... new study published today in the journal PNAS ... found that time of day and sleep deprivation have ... be crucial when looking at the best time of ... heart disease, and for administering medicines effectively. , Researchers ... Cancer Research, London, investigated the links between sleep deprivation, ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2
... Stockholders Approve Board Authority to Implement Reverse Stock Split and ... of Total Shares and Authorized Shares, NEW HAVEN, Conn., ... that a Special Meeting of,Stockholders was held at the Omni ... At the meeting, shareholders voted to approve amendments to the,Company,s ...
... - For Full Year 2007, Strong Operating Earnings and Tax Benefits Drive ... and Product Sales Both Grow 14% -, - In 2008, Gen-Probe Expects ... Driving Anticipated EPS of ... GPRO ) today reported strong financial results for the fourth,quarter and ...
... DENVER, Feb. 13 Rocky Mountain Biosystems, ... announced receipt of a,grant award of approximately ... of Allergy and Infectious Diseases at the ... Self-Administered Vaccination Electromechanical,(SAVE) technology for influenza vaccination. ...
Cached Biology Technology:Vion Pharmaceuticals Holds Special Meeting of Stockholders 2Vion Pharmaceuticals Holds Special Meeting of Stockholders 3Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 2Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 3Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 4Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 5Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 6Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 7Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 8Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 9Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 10Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 11Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 12Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 13Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 14Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 15Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 16NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza 2
(Date:7/11/2014)... Institute of Standards and Technology (NIST) need a ... they often prove that necessity is truly the ... for M. Lorna De Leoz and Stephen Stein, ... glycomics. Glycomics is the study of the abundant, ... to proteins and lipids and influence cellular processes, ...
(Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... and the Manchester Metropolitan University have carried out the ... amber more than 30 millions years ago. , The ... the Dominican (Caribbean) regions has revealed new insights into ... period. , It is the first time ancient spiders ...
... at the National Institute of Allergy and Infectious Disease ... (NIH), have identified a critical human cell surface molecule ... virus that causes Kaposi's sarcoma and certain forms of ... HIV/AIDS, and it typically manifests as multiple purple-hued skin ...
... the amino acid supplement L-arginine following a heart attack ... may be associated with an increased risk of death, ... of JAMA. , L-arginine is a widely available dietary ... with hypertension, angina, heart failure and sexual dysfunction, according ...
Cached Biology News:Amber reveals ecology of 30 million year old spiders 2Landmark discovery of a Kaposi's sarcoma-associated herpesvirus receptor 2Landmark discovery of a Kaposi's sarcoma-associated herpesvirus receptor 3Little known DNA repair enzyme may be a tumor suppressor gene 2
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse anti human pro-Relaxin-2...
Mouse Anti-Human Kallikrein 2 (Hk2)...
Biology Products: